{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T09:44:08Z","timestamp":1743500648307},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,2,16]],"date-time":"2010-02-16T00:00:00Z","timestamp":1266278400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s00228-010-0789-2","type":"journal-article","created":{"date-parts":[[2010,2,15]],"date-time":"2010-02-15T10:09:31Z","timestamp":1266228571000},"page":"619-625","source":"Crossref","is-referenced-by-count":24,"title":["Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults\u2014a nationwide registry-based study"],"prefix":"10.1007","volume":"66","author":[{"given":"Bjorn","family":"Gudbjornsson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sigurdur B.","family":"Thorsteinsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helgi","family":"Sigvaldason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rannveig","family":"Einarsdottir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus","family":"Johannsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helga","family":"Zoega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Halldorsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gudmundur","family":"Thorgeirsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,2,16]]},"reference":[{"key":"789_CR1","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/0006-291X(89)91819-6","volume":"164","author":"GD Rosen","year":"1989","unstructured":"Rosen GD, Birkenmeier TM, Raz A, Holtzam MJ (1989) Identification of a cyclooxygenase-related gene and its potential role in prostaglandin formation. Biochem Biophys Res Commun 164:1358\u20131365","journal-title":"Biochem Biophys Res Commun"},{"key":"789_CR2","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1073\/pnas.86.5.1657","volume":"86","author":"A Raz","year":"1989","unstructured":"Raz A, Wyche A, Needleman P (1989) Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phases. Proc Natl Acad Sci USA 86:1657\u20131661","journal-title":"Proc Natl Acad Sci USA"},{"key":"789_CR3","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1073\/pnas.87.9.3373","volume":"87","author":"JW Han","year":"1990","unstructured":"Han JW, Sadowski H, Young DA, Macara IG (1990) Persistent induction of cyclooxygenase in p60v-src-transformed 3T3 fibroblasts. Proc Natl Acad Sci USA 87:3373\u20133377","journal-title":"Proc Natl Acad Sci USA"},{"key":"789_CR4","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/newbio231232a0","volume":"231","author":"JR Vane","year":"1971","unstructured":"Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231:232\u2013235","journal-title":"Nat New Biol"},{"key":"789_CR5","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1073\/pnas.88.7.2692","volume":"88","author":"WL Xie","year":"1991","unstructured":"Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL (1991) Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 88:2692\u20132696","journal-title":"Proc Natl Acad Sci USA"},{"key":"789_CR6","doi-asserted-by":"crossref","first-page":"12866","DOI":"10.1016\/S0021-9258(18)98774-0","volume":"266","author":"DA Kujubu","year":"1991","unstructured":"Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR (1991) TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase\/cyclooxygenase homologue. J Biol Chem 266:12866\u201312872","journal-title":"J Biol Chem"},{"key":"789_CR7","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J","volume":"41","author":"LS Simon","year":"1998","unstructured":"Simon LS, Lanza FL, Lipsky PE et al (1998) Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 41:1591\u20131602","journal-title":"Arthritis Rheum"},{"key":"789_CR8","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0009-9236(99)70113-X","volume":"65","author":"EW Ehrich","year":"1999","unstructured":"Ehrich EW, Dallob A, De Lepeleire I et al (1999) Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 65:336\u2013347","journal-title":"Clin Pharmacol Ther"},{"key":"789_CR9","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(08)61490-7","volume":"372","author":"JA Baron","year":"2008","unstructured":"Baron JA, Sandler RS, Bresalier RS et al (2008) Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 372:1756\u20131764","journal-title":"Lancet"},{"key":"789_CR10","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","volume":"352","author":"SD Solomon","year":"2005","unstructured":"Solomon SD, McMurray JJ, Pfeffer MA et al (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071\u20131080","journal-title":"N Engl J Med"},{"key":"789_CR11","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1056\/NEJMoa061355","volume":"355","author":"MM Bertagnolli","year":"2006","unstructured":"Bertagnolli MM, Eagle CJ, Zauber AG et al (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355:873\u2013884","journal-title":"N Engl J Med"},{"issue":"7","key":"789_CR12","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1371\/journal.pctr.0010033","volume":"1","author":"ADAPT Research Group","year":"2006","unstructured":"Research Group ADAPT (2006) Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer\u2019s Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 1(7):e33","journal-title":"PLoS Clin Trials"},{"key":"789_CR13","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","volume":"289","author":"PS Aisen","year":"2003","unstructured":"Aisen PS, Schafer KA, Grundman M et al (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289:2819\u20132826","journal-title":"JAMA"},{"key":"789_CR14","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0140-6736(04)17514-4","volume":"364","author":"P J\u00fcni","year":"2004","unstructured":"J\u00fcni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M (2004) Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364:2021\u20132029","journal-title":"Lancet"},{"key":"789_CR15","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/bmj.330.7504.1366","volume":"330","author":"J Hippisley-Cox","year":"2005","unstructured":"Hippisley-Cox J, Coupland C (2005) Risk of myocardial infarction in patients taking cyclooxygenase inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 330:1366\u20131372","journal-title":"BMJ"},{"key":"789_CR16","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(05)17864-7","volume":"365","author":"DJ Graham","year":"2005","unstructured":"Graham DJ, Campen D, Hui R et al (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase-2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365:475\u2013481","journal-title":"Lancet"},{"key":"789_CR17","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1161\/01.CIR.0000127578.21885.3E","volume":"109","author":"DH Solomon","year":"2004","unstructured":"Solomon DH, Schneeweiss S, Glynn RJ et al (2004) Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109:2068\u20132073","journal-title":"Circulation."},{"key":"789_CR18","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/clpt.2008.204","volume":"85","author":"EL Fosb\u00f8l","year":"2009","unstructured":"Fosb\u00f8l EL, Gislason GH, Jacobsen S et al (2009) Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 85:190\u2013197","journal-title":"Clin Pharmacol Ther"},{"key":"789_CR19","unstructured":"Statistics Iceland (2009) Population by sex and age. www.statice.is"},{"key":"789_CR20","unstructured":"Gebski V, Leung O, McNeil D, Lunn D (1992) Statistical package for interactive data analysis (SPIDA), version 6. Macquarie University, Sydney"},{"key":"789_CR21","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/archinte.168.11.1219","volume":"168","author":"MD Haag","year":"2008","unstructured":"Haag MD, Bos MJ, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH (2008) Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Arch Intern Med 168:1219\u20131224","journal-title":"Arch Intern Med"},{"key":"789_CR22","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1161\/STROKEAHA.107.508549","volume":"39","author":"CL Roumie","year":"2008","unstructured":"Roumie CL, Mitchel EF Jr, Kaltenbach L, Arbogast PG, Gideon P, Griffin MR (2008) Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke. Stroke 39:2037\u20132045","journal-title":"Stroke"},{"key":"789_CR23","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/archinte.165.9.978","volume":"165","author":"SP Johnsen","year":"2005","unstructured":"Johnsen SP, Larsson H, Tarone RE et al (2005) Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 165:978\u2013984","journal-title":"Arch Intern Med"},{"key":"789_CR24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.7326\/0003-4819-142-3-200502010-00013","volume":"142","author":"A Finckh","year":"2005","unstructured":"Finckh A, Aronson MD (2005) Cardiovascular risks of cyclo-oxygenase-2 inhibitors: where do we stand now? Ann Intern Med 142:157\u2013164","journal-title":"Ann Intern Med"},{"key":"789_CR25","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/pds.1815","volume":"18","author":"C Varas-Lorenzo","year":"2009","unstructured":"Varas-Lorenzo C, Castellsague J, Stang MR, Perez-Gutthann S, Aguado J, Rodriguez LA (2009) The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada. Pharmacoepidemiol Drug Saf 18:1016\u20131025","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"789_CR26","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1001\/jama.296.13.jrv60011","volume":"296","author":"P McGettigan","year":"2006","unstructured":"McGettigan P, Henry D (2006) Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296:1633\u20131644","journal-title":"JAMA"},{"key":"789_CR27","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1161\/CIRCULATIONAHA.106.616219","volume":"113","author":"GH Gislason","year":"2006","unstructured":"Gislason GH, Jacobsen S, Rasmussen JN et al (2006) Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 113:2906\u20132913","journal-title":"Circulation"},{"key":"789_CR28","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/ard.2007.076760","volume":"68","author":"NJ Goodson","year":"2009","unstructured":"Goodson NJ, Brookhart AM, Symmons DP, Silman AJ, Solomon DH (2009) Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis 68:367\u2013372","journal-title":"Ann Rheum Dis"},{"key":"789_CR29","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/FJC.0b013e318157f72d","volume":"50","author":"CD Funk","year":"2007","unstructured":"Funk CD, FitzGerald GA (2007) COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 50:470\u2013479","journal-title":"J Cardiovasc Pharmacol"},{"key":"789_CR30","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2174\/187152908786786250","volume":"8","author":"N Bunimov","year":"2008","unstructured":"Bunimov N, Laneuville O (2008) Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis. Cardiovasc Hematol Disord Drug Targets 8:268\u2013277","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"789_CR31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1172\/JCI200113418","volume":"108","author":"C Patrono","year":"2001","unstructured":"Patrono C, Patrignani P, Garcia Rodriguez L (2001) Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 108:7\u201313","journal-title":"J Clin Invest"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-010-0789-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-010-0789-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-010-0789-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T01:11:54Z","timestamp":1634951514000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-010-0789-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,16]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["789"],"URL":"https:\/\/doi.org\/10.1007\/s00228-010-0789-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,16]]}}}